Liquid Biopsies in Drug Development: Where They Add Value Today & What Still Needs Work

• Where liquid biopsies are currently delivering the most value across the drug development lifecycle, and where teams remain cautious 
• What are the key practical challenges of integrating liquid biopsy endpoints into clinical development programs 
• What needs to change, technically, operationally, or regulatorily, to enable broader and more confident adoption 

Speakers:

Fernando Cruz-Guilloty

Scientific Director, Oncology - Precision Medicine & Diagnostics Lead

Johnson & Johnson Innovative Medicine

Paul robbins

VP, Translational Sciences

Allogene Therapeutics

Steffan Ho

Vice President & Head of Translational Oncology

Pfizer

Ben Herzberg

Assistant Professor, Medicine

Columbia University Irving Medical Center